TY  - GEN
AU  - Bonnefoi,H
AU  - Jacot,W
AU  - Saghatchian,M
AU  - Moldovan,C
AU  - Venat-Bouvet,L
AU  - Zaman,K
AU  - Matos,E
AU  - Petit,T
AU  - Bodmer,A
AU  - Quenel-Tueux,N
AU  - Chakiba,C
AU  - Vuylsteke,P
AU  - Jerusalem,G
AU  - Brain,E
AU  - Tredan,O
AU  - Messina,C G M
AU  - Slaets,L
AU  - Cameron,D
TI  - Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
SN  - 1569-8041
PY  - 2016///0224
KW  - Adult
KW  - Aged
KW  - Anthracyclines
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Chemotherapy, Adjuvant
KW  - methods
KW  - Cyclophosphamide
KW  - Docetaxel
KW  - Epirubicin
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Lapatinib
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Quinazolines
KW  - Receptor, ErbB-2
KW  - biosynthesis
KW  - Taxoids
KW  - Trastuzumab
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1093/annonc/mdu551
ER  -